A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Trial Profile

A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2016

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Acromegaly; Carcinoid tumour; Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 02 May 2016 Trial design changed from parallel to single group assignment.
    • 14 Mar 2012 Planned number of patients changed from 60 to 77 as reported by ClinicalTrials.gov.
    • 15 Jan 2009 Results were presented at the 2009 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top